Average Insider

Where insiders trade, we follow

$AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Elisabet de los Pinos
CEO
106
Employees
$7.39
Current Price
$333.39M
Market Cap
52W Low$4.73
Current$7.3955.4% above low, 44.6% below high
52W High$9.54

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00--All Sells
Sells11$39,044,986.806,922,870
2 monthsBuys00--All Sells
Sells22$39,127,387.566,934,608
3 monthsBuys00--All Sells
Sells22$39,127,387.566,934,608
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
May 7, 2026
Matrix Capital Management Company, LP
10% Owner
Sale6,922,870$5.64$39,044,986.80View Details
Apr 16, 2026
Kilroy Conor
Chief Legal Officer and Secretary.
Sale11,738$7.02$82,400.76View Details
12 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Mar 31, 2026
EPS
Estimated-$0.43
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Mar 23, 2026
EPS
Estimated-$0.43
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.5.2